Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum Pharmaceuticals to Participate in Fireside Chat at the Piper Jaffray 27th Annual Healthcare Conference

HOUSTON--(BUSINESS WIRE)--Nov. 24, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell, President and CEO, will participate in an analyst-led fireside chat at the 27th Annual Piper Jaffray Healthcare Conference. The fireside chat will take place on Wednesday, December 2, 2015 at 12:30 p.m. EST at The New York Palace Hotel.

A live webcast may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO, 832-384-1116
amusso@bellicum.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com